Nektar Therapeutics (NASDAQ:NKTR) Stock Rating Upgraded by Oppenheimer
Nektar Therapeutics (NASDAQ:NKTR – Get Free Report) was upgraded by equities research analysts at Oppenheimer from a “market ...
Nektar upgraded at Oppenheimer on upcoming mid-stage trial readout
Shares of Nektar Therapeutics (NASDAQ:NKTR) added ~9% in the premarket on Friday after Oppenheimer upgraded the biopharma to ...
Nektar Therapeutics Full Year 2024 Earnings: EPS Beats Expectations, Revenues Lag
Full Year 2024 Results Key Financial Results Revenue: US$98.4m (up 9.2% from ...
Zacks Investment Research on MSN2d
Nektar Q4 Loss Wider Than Expected, Pipeline in Focus, Stock Up
Nektar Therapeutics NKTR incurred an adjusted loss per share of 15 cents in the fourth quarter of 2024, wider than the Zacks ...
Nektar Therapeutics (NASDAQ:NKTR) Earns Market Perform Rating from William Blair
Nektar Therapeutics (NASDAQ:NKTR – Get Free Report)‘s stock had its “market perform” rating reissued by analysts at William ...
Nektar upgraded to Outperform at Oppenheimer ahead of rezpeg readout in June
Oppenheimer upgraded Nektar (NKTR) to Outperform from Perform with a $6 price target The firm is refreshing its model ahead of the company’s ...
Nektar up 12% to 91c after Oppenheimer upgrade with $6 target
EDT Nektar (NKTR) up 12% to 91c after Oppenheimer upgrade with $6 targetLight Up your Portfolio with Spark:Easily identify stocks' risks ...
Nektar Therapeutics (NKTR) Q4 2024 Earnings Call Highlights: Strategic Advances Amid Financial ...
Despite a net loss, Nektar Therapeutics (NKTR) showcases promising developments in its autoimmune pipeline and maintains a ...
WTOP News3d
Nektar: Q4 Earnings Snapshot
SAN FRANCISCO (AP) — SAN FRANCISCO (AP) — Nektar Therapeutics (NKTR) on Wednesday reported fourth-quarter earnings of $7.3 million. The San Francisco-based company said it had net income of 3 ...